Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (PRECISION I) Lee, E., Rodon, J., Demeure, M., Deming, D., Federman, N., McKean, M., Spira, A., Kwiatkowski, D., Hussein, M., Gordon, E., Crockett, D., Ganjoo, K., Schulte, B., Cranmer, L., Schmid, A., Navarro, W., Itri, L., Iyer, G. ACADEMIC PRESS INC ELSEVIER SCIENCE. 2023: S185

View details for DOI 10.1016/j.ygyno.2023.06.204

View details for Web of Science ID 001079556100293